MUC1 is a heterodimeric mucin-like glycoprotem expressed by ductal epithelial cells of several organs. MUC1 is overexpressed and differentially glycosylated by many tumors. Results of studies conducted in our laboratory and in other laboratories during the past several years have led us to hypothesize that one major function of the large tandem-repeat containing extracellular fragment of the MUC1 protein is to aid in the configuration of adhesive and anti-adhesive properties of the surface of cells on which it is expressed. On normal epithelial cells, the anti-adhesive properties of MUC1 are predicted to contribute to the maintenance of an apical such that is exposed to a lumenal cavity and is not in association with other cells. It is predicted that MUC1 expression can serve to reconfigure the cell surface adhesion properties with molecular specificity by simultaneously dismupting existing interactions between some adhesion molecules and by confening new adhesive properties through direct adhesion to receptors on other cells or tissues. Experiments proposed in this application will test this hypothesis and investigate the role of MUC1 in tumor invasion and metastasis throughout different organ sites. A second molecular component of cell surface associated heterodimeric MUCI is the integral membrane protein, which contains a cytoplasmic tail, transmembrane domain and a short exiracellular domain that associates with the large extracellular fragment that mediates the adhesion and anti-adhesion functions of this protein. The cytoplasmic tail is phosphorylated and has been implicated as interfacing with beta catenin, GSK3I3, c-Src, EGFR and other ethB receptors, and with Grb2-Sos signal transduction pathways in some cells. The cytoplasmic tail is also believed to associate with cytoskeletal elements including actin, and under some conditions can be recycled from the cell surface to the trans-Golgi network. The precise function of the membrane associated domain of MUC1 and its role in signal transduction has not been established. We propose to test two non-mutually exclusive hypotheses of functions for this component of the MUC1 protein. The first is that the transmembrane and cytoplasmic tail domains function to communicate information about the status of the cell surface to the interior compartments of the cell. In this model we postulate that the exiracellular domain of MUC1 can function as a molecular sensor of certain extracellular conditions (pH and adhesion status) and that alterations in MUC 1 structure or binding status can be communicated to internal compartments of the cell through the transmernbrane domain and cytoplasmic tail. The second hypothesis posits that the transmembrane domain and/or cytoplasmic tail play a structural role that supports the adhesion and anti-adhesion properties of MUC1.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
3R01CA057362-12S1
Application #
7169194
Study Section
Pathology B Study Section (PTHB)
Program Officer
Ogunbiyi, Peter
Project Start
1992-09-01
Project End
2008-02-28
Budget Start
2006-03-01
Budget End
2008-02-28
Support Year
12
Fiscal Year
2006
Total Cost
$5,512
Indirect Cost
Name
University of Nebraska Medical Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
168559177
City
Omaha
State
NE
Country
United States
Zip Code
68198
Fink, Darci M; Steele, Maria M; Hollingsworth, Michael A (2016) The lymphatic system and pancreatic cancer. Cancer Lett 381:217-36
Hanson, Ryan L; Brown, Roger B; Steele, Maria M et al. (2016) Identification of FRA-1 as a novel player in pancreatic cancer in cooperation with a MUC1: ERK signaling axis. Oncotarget 7:39996-40011
Liu, X; Caffrey, T C; Steele, M M et al. (2014) MUC1 regulates cyclin D1 gene expression through p120 catenin and ?-catenin. Oncogenesis 3:e107
Liu, Xiang; Huang, Huocong; Remmers, Neeley et al. (2014) Loss of E-cadherin and epithelial to mesenchymal transition is not required for cell motility in tissues or for metastasis. Tissue Barriers 2:e969112
Thege, Fredrik I; Lannin, Timothy B; Saha, Trisha N et al. (2014) Microfluidic immunocapture of circulating pancreatic cells using parallel EpCAM and MUC1 capture: characterization, optimization and downstream analysis. Lab Chip 14:1775-84
Radhakrishnan, Prakash; Dabelsteen, Sally; Madsen, Frey Brus et al. (2014) Immature truncated O-glycophenotype of cancer directly induces oncogenic features. Proc Natl Acad Sci U S A 111:E4066-75
Liu, Xiang; Yi, Chunhui; Wen, Yunfei et al. (2014) Interactions between MUC1 and p120 catenin regulate dynamic features of cell adhesion, motility, and metastasis. Cancer Res 74:1609-20
Bunt, Stephanie K; Mohr, Ashley M; Bailey, Jennifer M et al. (2013) Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer. Cancer Immunol Immunother 62:225-36
Remmers, Neeley; Anderson, Judy M; Linde, Erin M et al. (2013) Aberrant expression of mucin core proteins and o-linked glycans associated with progression of pancreatic cancer. Clin Cancer Res 19:1981-93
Radhakrishnan, Prakash; Grandgenett, Paul M; Mohr, Ashley M et al. (2013) Expression of core 3 synthase in human pancreatic cancer cells suppresses tumor growth and metastasis. Int J Cancer 133:2824-33

Showing the most recent 10 out of 59 publications